Sign In
Buy BCRX
$8.25
-0.0900 (-1.08%)
At Close: Jun 03, 2026
BioCryst to Present at 41st Annual J.P. Morgan Healthcare Conference
07:00am, Wednesday, 04'th Jan 2023
RESEARCH TRIANGLE PARK, N.C., Jan. 04, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 41st Annual J.P. Morgan Healthcare C
BioCryst Pharmaceuticals: More Aggressive Growth For Orladeyo
04:47pm, Tuesday, 20'th Dec 2022
As a stellar drug for hereditary angioedema, BioCryst Pharmaceuticals' Orladeyo is enjoying strong sales reactions in its second year of launch. Coupled with ongoing global market expansions and on to
BioCryst (BCRX) Down as it Discontinues Developing PNH Drug
01:33pm, Friday, 16'th Dec 2022
BioCryst (BCRX) down as it drops the development of BCX9930, which was being evaluated for PNH.
BCRX Stock Sinks as BioCryst Discontinues Drug Development
10:19am, Thursday, 15'th Dec 2022
BioCryst Pharmaceuticals (NASDAQ: BCRX ) stock is falling on Thursday after revealing the end of development for BCX9930. BCX9930 was in development alongside BCX10013 as a Factor D inhibitor.
BioCryst to discontinue development of drug
08:52am, Thursday, 15'th Dec 2022
Shares of BioCryst Pharmaceuticals Inc. were down about 5% in premarket trading on Thursday after the company said it halted development of BCX9930, which was being tested as a treatment for paroxysma
BioCryst to Present at JMP Securities Hematology & Oncology Summit
07:00am, Monday, 05'th Dec 2022
RESEARCH TRIANGLE PARK, N.C., Dec. 05, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present virtually at the JMP Securities Hematology
3 Biotechnology stocks under 10 dollars to buy now
11:30am, Saturday, 26'th Nov 2022
Here are three inexpensive biotech stocks with a bright future ahead of them.
BioCryst Presents Real-World Data Showing Rapid and Sustained HAE Attack Rate Reduction After Beginning ORLADEYO® (berotralstat), Regardless of Prior Prophylactic Therapy
01:00pm, Thursday, 10'th Nov 2022 GlobeNewswire Inc.
RESEARCH TRIANGLE PARK, N.C., Nov. 10, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new real-world data demonstrating rapid, sustained reduction of patient
BioCryst to Present at Upcoming Investor Conferences
12:00pm, Wednesday, 09'th Nov 2022 GlobeNewswire Inc.
RESEARCH TRIANGLE PARK, N.C., Nov. 09, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the following investor conferences:
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11:00am, Friday, 04'th Nov 2022 GlobeNewswire Inc.
RESEARCH TRIANGLE PARK, N.C., Nov. 04, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors gran
Expert Ratings for BioCryst Pharmaceuticals
07:15pm, Wednesday, 02'nd Nov 2022 Benzinga
Analysts have provided the following ratings for BioCryst Pharmaceuticals (NASDAQ:BCRX) within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
0
4 Analysts Have This to Say About BioCryst Pharmaceuticals
05:37pm, Wednesday, 02'nd Nov 2022 Benzinga
Within the last quarter, BioCryst Pharmaceuticals (NASDAQ:BCRX) has observed the following analyst ratings:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
0
1
3
0
Benzinga's Top Ratings Upgrades, Downgrades For November 2, 2022
02:06pm, Wednesday, 02'nd Nov 2022 Benzinga
Upgrades
According to Evercore ISI Group, the prior rating for BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) was changed from In-Line to Outperform. In the third quarter, BioCryst Pharmaceuticals showed
Why Harsco Shares Surged Over 22%; Here Are 80 Biggest Movers From Yesterday
09:07am, Wednesday, 02'nd Nov 2022 Benzinga
Gainers
Abiomed, Inc. (NASDAQ: ABMD) shares surged 49.9% to settle at $377.82 on Tuesday after Johnson & Johnson announced it will acquire the company . Also, the company reported better-than-expec
BioCryst Pharmaceuticals (BCRX) Q3 2022 Earnings Call Transcript
07:00pm, Tuesday, 01'st Nov 2022 The Motley Fool
BCRX earnings call for the period ending September 30, 2022.
